Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

被引：17
|
作者：
Mann, Johannes F. E. [1 ,2 ]
Muskiet, Marcel H. A. [3 ]
机构：
[1] KfH Kidney Ctr, 15 Isoldenst, D-80804 Munich, Germany
[2] Friedrich Alexander Univ, Univ Hosp, Dept Nephrol & Hypertens, Erlangen, Germany
[3] Vrije Univ, Amsterdam Univ, Med Ctr, Dept Internal Med,Diabet Ctr, Amsterdam, Netherlands
来源：
KIDNEY INTERNATIONAL | 2021年 / 99卷 / 02期
关键词：
RENAL OUTCOMES; CARDIOVASCULAR OUTCOMES; LIRAGLUTIDE;
D O I：
10.1016/j.kint.2020.08.036
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：314 / 318
页数：5
相关论文
共 50 条
  • [31] The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
    Thomas, Merlin C.
    DIABETES & METABOLISM, 2017, 43 : 2S20 - 2S27
  • [32] Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Bahtiyar, Gul
    Pujals-Kury, Jean
    Sacerdote, Alan
    CURRENT DIABETES REPORTS, 2018, 18 (10)
  • [33] Renal effects of GLP-1 agonists in type 2 diabetes
    Elbert, Alicia
    Castellaro, Carlos
    Litwak, Leon
    Inserra, Felipe
    Wassermann, Alfredo
    Sinay, Isaac
    MEDICINA-BUENOS AIRES, 2022, 82 (04) : 576 - 590
  • [34] THE ROLE OF DPP-4 INHIBITORS IN TYPE-2 DIABETES PATIENTS WITH CHRONIC KIDNEY DISEASE
    Alqurashi, Mishal Yousef
    Alharthi, Khalid Faisal
    Alshehri, Abdulaziz Abdulrahman
    Alharbi, Yazeed Khalid
    Sanousi, Mohammad Abdulmunem
    Almazyed, Anas Abdullah
    Alghamdi, Khulud Saeed
    Alrashidi, Sarah Musaad
    Qaeed, Waad Abdullah
    Alasmari, Amjad Aedh
    Alzahrani, Fahad Abdulrahman D.
    Ahmed, Alazmi Ibrahim
    PHARMACOPHORE, 2021, 12 (03): : 91 - 94
  • [35] GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
    Nauck, Michael A.
    Quast, Daniel R.
    Wefers, Jakob
    Meier, Juris J.
    MOLECULAR METABOLISM, 2020, 46
  • [36] Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No
    Madsbad, Sten
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (02) : 132 - 136
  • [37] The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
    van Baar, Michael J. B.
    van der Aart, Annemarie B.
    Hoogenberg, Klaas
    Joles, Jaap A.
    Heerspink, Hiddo J. L.
    van Raalte, Daniel H.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2019, 10
  • [38] Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
    McReelis, Kylen D.
    Lovshin, Julie A.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2017, 52 : S4 - S7
  • [39] Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes
    Abrahami, Devin
    Yin, Hui
    Yu, Oriana H. Y.
    Pollak, Michael N.
    Azoulay, Laurent
    EPIDEMIOLOGY, 2018, 29 (02) : 246 - 253
  • [40] Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Singh, Awadhesh Kumar
    Singh, Ritu
    WORLD JOURNAL OF CARDIOLOGY, 2022, 14 (06): : 329 - 342
12345